Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
03 Enero 2024 - 10:28AM
Business Wire
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a
global biotechnology company developing, manufacturing, and
commercializing novel therapies to treat life-threatening diseases,
closed its previously announced exclusive, worldwide license
agreement with Novartis Pharma AG (Novartis) for certain Legend
Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies
targeting Delta-like ligand protein 3 (DLL3), including Legend
Biotech’s existing autologous CAR-T cell therapy candidate, LB2102
(NCT05680922).1 Under the terms of the license agreement, Legend
Biotech will receive a $100 million upfront cash payment.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to
treating, and one day curing, life-threatening diseases.
Headquartered in Somerset, New Jersey, we are developing advanced
cell therapies across a diverse array of technology platforms,
including autologous and allogeneic chimeric antigen receptor
T-cell, gamma-delta T cell and natural killer (NK) cell-based
immunotherapy. From our three R&D sites around the world, we
apply these innovative technologies to pursue the discovery of
cutting-edge therapeutics for patients worldwide.
Learn more at https://legendbiotech.com and follow us on X
(formerly Twitter) and LinkedIn.
References
_________________ 1 ClinicalTrials.gov. DLL3-Directed Chimeric
Antigen Receptor T-cells in Subjects With Extensive Stage Small
Cell Lung Cancer. Available at:
https://classic.clinicaltrials.gov/ct2/show/NCT05680922. Last
accessed Nov 2023.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240103368335/en/
Press contact: Alexandra Ventura, Corporate
Communications & Investor Relations, Legend Biotech
alex.ventura@legendbiotech.com 732-850-5598
Investor contact: Jessie Yeung, Head of Investor
Relations & Public Relations, Legend Biotech
jessie.yeung@legendbiotech.com
Legend Biotech (NASDAQ:LEGN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Legend Biotech (NASDAQ:LEGN)
Gráfica de Acción Histórica
De May 2023 a May 2024
